Literature DB >> 34292655

Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase.

Taylor K Johnson1, Daniel A Bochar1, Nathalie M Vandecan1, Jessica Furtado1, Michael P Agius1, Sameer Phadke1, Matthew B Soellner1.   

Abstract

Allosteric inhibitors of Abl kinase are being explored in the clinic, often in combination with ATP-site inhibitors of Abl kinase. However, there are conflicting data on whether both ATP-competitive inhibitors and myristoyl-site allosteric inhibitors can simultaneously bind Abl kinase. Here, we determine whether there is synergy or antagonism between ATP-competitive inhibitors and allosteric inhibitors of Abl. We observe that clinical ATP-competitive inhibitors are not synergistic with allosteric ABL inhibitors, however, conformation-selective ATP-site inhibitors that modulate the global conformation of Abl can afford synergy. We demonstrate that kinase conformation is the key driver to simultaneously bind two compounds to Abl kinase. Finally, we explore the interaction of allosteric and conformation selective ATP-competitive inhibitors in a series of biochemical and cellular assays.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  Abl; allostery; inhibitors; kinase; synergy

Mesh:

Substances:

Year:  2021        PMID: 34292655      PMCID: PMC8405588          DOI: 10.1002/anie.202105351

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   16.823


  20 in total

Review 1.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Authors:  Doriano Fabbro; Paul W Manley; Wolfgang Jahnke; Janis Liebetanz; Alexandra Szyttenholm; Gabriele Fendrich; Andre Strauss; Jianming Zhang; Nathanael S Gray; Francisco Adrian; Markus Warmuth; Xavier Pelle; Robert Grotzfeld; Frederic Berst; Andreas Marzinzik; Sandra W Cowan-Jacob; Pascal Furet; Jürgen Mestan
Journal:  Biochim Biophys Acta       Date:  2010-03

3.  Selective Proteolysis to Study the Global Conformation and Regulatory Mechanisms of c-Src Kinase.

Authors:  Michael P Agius; Kristin S Ko; Taylor K Johnson; Frank E Kwarcinski; Sameer Phadke; Eric J Lachacz; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2019-07-09       Impact factor: 5.100

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  A myristoyl/phosphotyrosine switch regulates c-Abl.

Authors:  Oliver Hantschel; Bhushan Nagar; Sebastian Guettler; Jana Kretzschmar; Karel Dorey; John Kuriyan; Giulio Superti-Furga
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

6.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

7.  Allosteric interactions between the myristate- and ATP-site of the Abl kinase.

Authors:  Roxana E Iacob; Jianming Zhang; Nathanael S Gray; John R Engen
Journal:  PLoS One       Date:  2011-01-10       Impact factor: 3.240

8.  Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.

Authors:  Florian Grebien; Oliver Hantschel; John Wojcik; Ines Kaupe; Boris Kovacic; Arkadiusz M Wyrzucki; Gerald D Gish; Sabine Cerny-Reiterer; Akiko Koide; Hartmut Beug; Tony Pawson; Peter Valent; Shohei Koide; Giulio Superti-Furga
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

9.  Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Authors:  Jianming Zhang; Francisco J Adrián; Wolfgang Jahnke; Sandra W Cowan-Jacob; Allen G Li; Roxana E Iacob; Taebo Sim; John Powers; Christine Dierks; Fangxian Sun; Gui-Rong Guo; Qiang Ding; Barun Okram; Yongmun Choi; Amy Wojciechowski; Xianming Deng; Guoxun Liu; Gabriele Fendrich; André Strauss; Navratna Vajpai; Stephan Grzesiek; Tove Tuntland; Yi Liu; Badry Bursulaya; Mohammad Azam; Paul W Manley; John R Engen; George Q Daley; Markus Warmuth; Nathanael S Gray
Journal:  Nature       Date:  2010-01-13       Impact factor: 49.962

10.  Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.

Authors:  Panagis Filippakopoulos; Michael Kofler; Oliver Hantschel; Gerald D Gish; Florian Grebien; Eidarus Salah; Philipp Neudecker; Lewis E Kay; Benjamin E Turk; Giulio Superti-Furga; Tony Pawson; Stefan Knapp
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.